Designs for Single- or Multiple-Agent Phase I Trials
From MaRDI portal
Publication:3445286
DOI10.1111/J.0006-341X.2004.00215.XzbMATH Open1274.62750OpenAlexW2046121575WikidataQ30434355 ScholiaQ30434355MaRDI QIDQ3445286FDOQ3445286
Authors: Mark R. Conaway, Stephanie Dunbar, Shyamal D. Peddada 
Publication date: 11 June 2007
Published in: Biometrics (Search for Journal in Brave)
Full work available at URL: https://doi.org/10.1111/j.0006-341x.2004.00215.x
Recommendations
Applications of statistics to biology and medical sciences; meta analysis (62P10) Medical applications (general) (92C50)
Cites Work
- Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer
- Clinical Trials
- Design and Analysis of Phase I Clinical Trials
- A Random Walk Rule for Phase I Clinical Trials
- Confidence interval estimation subject to order restrictions
- Dose finding using the biased coin up-and-down design and isotonic regression
- Dose-finding with two agents in phase I oncology trials
- Continual Reassessment Method: A Likelihood Approach
- Practical Bayesian Guidelines for Phase IIB Clinical Trials
Cited In (17)
- Adaptive isotonic estimation of the minimum effective and peak doses in the presence of covariates
- Designs for Phase I Clinical Trials with Multiple Courses of Subjects at Different Doses
- Evaluation of phase I clinical trial designs for combinational agents along with guidance based on simulation studies
- Continual reassessment method for partial ordering
- A Latent Contingency Table Approach to Dose Finding for Combinations of Two Agents
- Cumulative cohort design for dose-finding
- A nonparametric Bayesian method for dose finding in drug combinations cancer trials
- Determining a Maximum‐Tolerated Schedule of a Cytotoxic Agent
- A Parallel Phase I/II Clinical Trial Design for Combination Therapies
- Adaptive clinical trial designs for phase I cancer studies
- Dose-finding with two agents in phase I oncology trials
- Two‐Dimensional Dose Finding in Discrete Dose Space
- Dose Finding for Continuous and Ordinal Outcomes with a Monotone Objective Function: A Unified Approach
- Bayesian phase I/II adaptively randomized oncology trials with combined drugs
- Dual-agent dose-finding in phase I clinical trial -- an extension of rapid enrollment design
- A phase I dose-finding study based on polychotomous toxicity responses
- A hierarchical Bayesian design for phase I trials of novel combinations of cancer therapeutic agents
This page was built for publication: Designs for Single- or Multiple-Agent Phase I Trials
Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q3445286)
